Gustavo E. Velásquez, MD, MPH
Assistant Professor
Medicine
School of Medicine

Based at the UCSF Center for Tuberculosis (tb.ucsf.edu), he works with the endTB consortium (endTB.org), the SMART4TB consortium (tbcenter.jhu.edu/smart4tb), and the AIDS Clinical Trials Group on Phase 2 and Phase 3 randomized controlled trials evaluating new shortened regimens for drug-susceptible and drug-resistant TB. He attends on the inpatient infectious diseases/HIV consult service and outpatient HIV and TB clinics at San Francisco General Hospital.

• An activist’s guide to shorter treatment for drug-resistant tuberculosis
  2023 McKenna L, Branigan D, Deborggraeve S, Frick M, Furin J, Galarza J, Gebhard A, Gupta S, Kaiser B, de Kruijf-Carter I, Kumar B, Mabote L, Mbenga M, Mirzayev F, Moses GK, Nguyen L, Nyang’wa BT, Pak S, …
• Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
  Lancet (London, England) 2023 Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, …
• Recent advances in the treatment of tuberculosis.
  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2023 Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR, Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, …
• Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru.
  Open forum infectious diseases 2023 Rahman RS, Tovar MA, Peinado J, Palomino JS, Ramirez C, Llanos-Zavalaga F, Peralta E, Valderrama G, Ramos Cordova LB, Sanchez Cortez LI, Rodriguez G, LaHood AN, Franke MF, Mitnick CD, Lecca L, …
• Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis.
  American journal of respiratory and critical care medicine 2023 Velásquez GE, Nahid P
• Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru.
  BMC infectious diseases 2023 Law S, Tovar MA, Franke MF, Calderon R, Palomino S, Valderrama G, Llanos F, Velásquez GE, Mitnick CD, Lecca L
• Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review.
  Journal of clinical medicine 2022 Jhaveri TA, Fung C, LaHood AN, Lindeborg A, Zeng C, Rahman R, Bain PA, Velásquez GE, Mitnick CD
• Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru.
  Microbiology spectrum 2022 Calderón RI, Jhaveri TA, Tovar MA, Palomino JS, Barreda NN, Sanabria OM, Peinado J, Ramirez C, Llanos Zavalaga LF, Valderrama G, Franke MF, Mitnick CD, Lecca L, Velásquez GE
• Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Tovar M, Peinado J, Palomino S, Llanos F, Ramírez C, Valderrama G, Calderón RI, Williams RB, Velásquez GE, Mitnick CD, Franke MF, Lecca L
• Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
  Trials 2021 Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, …
• Disparities in SARS-CoV-2 Vaccination-to-Infection Risk During the COVID-19 Pandemic in Massachusetts.
  JAMA health forum 2021 Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO
• Disparities in SARS-CoV-2 Vaccination-to-Infection Risk, Massachusetts 2020-2021
  medRxiv 2021 Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO
• Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic.
  JAMA network open 2021 Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu BO
• SARS-CoV-2 Testing Disparities in Massachusetts.
  medRxiv : the preprint server for health sciences 2020 Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu B
• Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series.
  Open forum infectious diseases 2020 Pearson JC, Dionne B, Richterman A, Vidal SJ, Weiss Z, Velásquez GE, Marty FM, Sax PE, Yawetz S
• Delayed Relapse of Paracoccidioidomycosis in the Central Nervous System: A Case Report.
  Open forum infectious diseases 2020 Rahman R, Davies L, Mohareb AM, Peçanha-Pietrobom PM, Patel NJ, Solomon IH, Meredith DM, Tsai HK, Guenette JP, Bhattacharyya S, Urday S, Velásquez GE
• The fourth national anti-tuberculosis drug resistance survey in Peru.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2020 Quispe N, Asencios L, Obregon C, Velásquez GE, Mitnick CD, Lindeborg M, Jave H, Solari L
• Quantitative assessment of the activity of antituberculosis drugs and regimens.
  Expert review of anti-infective therapy 2019 Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H
• Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
  American journal of respiratory and critical care medicine 2019 Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD
• Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group.
  Open forum infectious diseases 2019 Velásquez GE, Huaman MA, Powell KR, Cohn SE, Swaminathan S, Outlaw M, Schulte G, McNeil Q, Currier JS, Del Rio C, Castillo-Mancilla J
• Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
  American journal of respiratory and critical care medicine 2018 Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD
• Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2018 Velásquez GE, Davies GR, Mitnick CD
• A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept.
  Journal of general internal medicine 2018 Jain N, Doyon JB, Lazarus JE, Schaefer IM, Johncilla ME, Agoston AT, Dalal AK, Velásquez GE
• Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2017 Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD
• Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
  Antimicrobial agents and chemotherapy 2017 Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G
• Nutritional Status and Tuberculosis Risk in Adult and Pediatric Household Contacts.
  PloS one 2016 Aibana O, Acharya X, Huang CC, Becerra MC, Galea JT, Chiang SS, Contreras C, Calderon R, Yataco R, Velásquez GE, Tintaya K, Jimenez J, Lecca L, Murray MB
• Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
  Antimicrobial agents and chemotherapy 2016 Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB
• Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model.
  PLoS neglected tropical diseases 2016 Diakite I, Mooring EQ, Velásquez GE, Murray MB
• Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.
  BMC infectious diseases 2016 Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS
• Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Velásquez GE, Aibana O, Ling EJ, Diakite I, Mooring EQ, Murray MB
• Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S
• Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.
  Emerging infectious diseases 2011 Velásquez GE, Yagui M, Cegielski JP, Asencios L, Bayona J, Bonilla C, Jave HO, Yale G, Suárez C, Atwood S, Contreras CC, Shin SS